Last reviewed · How we verify

Influenza prevention — Treatment Landscape & Competitive Intelligence

Influenza prevention (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Influenza prevention, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Assorted Licensed Hand Sanitizer Grape 01 Licensed influenza vaccine Pfizer vaccine unknown
Licensed Influenza Vaccine 2 Licensed Influenza Vaccine 2 BioNTech Vaccine Not specified
Qiv qiv Pfizer Inactivated vaccine Influenza viruses

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 2 drugs in Influenza prevention
  2. BioNTech · 1 drug in Influenza prevention

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Influenza prevention:

Cite this brief

Drug Landscape (2026). Influenza prevention — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/influenza-prevention. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing